Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of LIK066 versus placebo or empagliflozin in type 2 diabetes mellitus patients with heart failure
2016-003084-19Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of licogliflozin in type 2 diabetes mellitus (T2DM) and heart failure (HF) (5 arms), sponsored by Novartis. Primary endpoint: Change from baseline in NT-proBNP at week 12. Started Apr 2017; status: terminated.
02
Drugs
licogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on 2016-003084-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003084-19.